HSA | FSA CARDS ARE NOW ACCEPTED

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on Peptides & GLP-1. Browse all Peptides & GLP-1 education

In April 2026, researchers published a landmark pharmacogenomics study in Nature that did something unusual in the weight management genetics space: it didn't just identify a gene associated with obesity or metabolic risk — it identified a genetic variant associated with outcomes specifically in people taking one type of medication, but not another. The variant is GIPR rs1800437. The medication type is tirzepatide, a dual GLP-1 and GIP receptor agonist. And the reason the finding is scientifically significant is precisely because it did not appear in GLP-1-only users in the same study. That specificity is the story.

What the 2026 Nature GWAS Was

A GWAS — genome-wide association study — simultaneously tests hundreds of thousands of genetic variants across a large population to find statistically significant associations with a specific trait or outcome. The 2026 study, conducted by the 23andMe Research Team and published in Nature, enrolled 27,885 individuals who were actively using GLP-1 receptor agonist medications. This is not a general population study. It is a pharmacogenomics study — specifically designed to find genetic variants that interact with medication use.

At nearly 28,000 participants, the study had substantial statistical power to detect even relatively modest genetic signals. The finding for rs1800437 passed a stringent significance threshold (genome-wide significance), meaning the association is unlikely to be a false positive. The study also performed meta-analysis across different ancestral groups, and the findings were directionally consistent — the signal held across populations, not just in one demographic subset.

The Core Finding: Tirzepatide-Specific, Not GLP-1-Wide

Here is the finding that distinguishes this study from most weight management genetics research: the rs1800437 association was detected in tirzepatide-treated individuals — and was not observed in individuals using GLP-1-only receptor agonists in the same study population.

That distinction is not a detail. It is the mechanism. To understand why, you have to understand what separates tirzepatide from GLP-1-only medications.

GLP-1-only agonists activate a single receptor pathway — the GLP-1 receptor — which regulates fullness signaling, gastric emptying, and insulin secretion. Tirzepatide activates two receptor pathways simultaneously: GLP-1 and GIP. The GIP receptor — encoded by the GIPR gene — is tirzepatide's second pharmacological target.

The rs1800437 variant encodes a partial loss-of-function change in the GIP receptor. When GIP receptor signaling is fully intact, it may help balance the physiological effects of simultaneous GLP-1 activation. When that GIP receptor function is reduced — as the C allele variant suggests — the balance between the two receptor pathways may shift. A GLP-1-only medication bypasses GIPR entirely, so a variant reducing GIPR function would have no opportunity to create that same dynamic. The biology explains the specificity of the finding.

What rs1800437 Is: The Glu354Gln Substitution

rs1800437 is a missense variant — a single nucleotide change in the GIPR gene (chromosome 19) that alters the amino acid encoded at position 354 of the GIP receptor protein. The standard form of the protein carries glutamic acid (Glu) at this position. The variant C allele substitutes glutamine (Gln) — a change written in scientific notation as p.Glu354Gln.

Research has characterized this substitution as a partial loss-of-function: the receptor still works, but with reduced signaling efficiency. The receptor isn't broken — it responds to GIP, but with a measurably lower output. That distinction matters: a complete loss-of-function variant would likely have been detected in earlier, smaller studies. A partial reduction in a receptor that only becomes relevant when that receptor is simultaneously targeted by a medication is exactly the kind of signal that requires a large, medication-specific pharmacogenomics study to surface.

The effect allele is C (associated with reduced GIP receptor signaling). The protective allele is G (associated with more typical receptor function). Three genotypes are possible: G/G (zero effect alleles), G/C (one effect allele), and C/C (two effect alleles).

Why This Variant Wasn't Detected in Earlier GLP-1 Research

Before dual-receptor agonists became widely available, nearly all pharmacogenomics research on weight management medications studied GLP-1-only compounds. GIPR rs1800437 would have been invisible in those studies — not because the variant isn't real, but because the receptor it affects wasn't being pharmacologically engaged.

This is a broader lesson in pharmacogenomics: the genetic variants that matter for a given medication are not always the same as the variants that matter for the drug's therapeutic class as a whole. As dual-receptor and multi-receptor medications become more common in weight management, the genetic landscape of who responds to what — and who experiences which tolerability profile — becomes more specific, not less. GIPR rs1800437 is an early example of that specificity in action.

Direct Genotyping: Why It Matters at This Locus

Not all genetic testing platforms measure rs1800437 directly. Some platforms infer variant status through imputation — using statistical models based on nearby variants to estimate what an unmeasured position is likely to be. Imputation is a practical approach for many variants, but it introduces uncertainty, particularly for missense variants in pharmacologically relevant genes where precision matters.

The PlexusDx Precision Peptide Genetic Test directly genotypes rs1800437 on the Illumina Global Screening Array. This means the variant is measured precisely from your DNA — not estimated. For a pharmacogenomics-relevant SNP identified at genome-wide significance in a landmark study, direct measurement rather than imputation is the appropriate standard.

GIPR rs1800437 Within the 34 Weight Management Insights

The Precision Peptide Genetic Test includes rs1800437 as one of 34 weight management genetic insights — covering the full genetic architecture of appetite regulation, fat metabolism, insulin signaling, and hormonal response. The panel analyzes 150+ total insights across 14 biological pathways, using 57 SNPs across 48 genes on the Illumina Global Screening Array in CLIA-certified labs.

Your GIPR rs1800437 genotype does not independently determine your weight management outcomes. It is one layer of a genetic picture that also includes FTO, MC4R, PPARG, TCF7L2, ADIPOQ, LEPR, IGF1, and CD36. The test does not recommend or prescribe any medication or protocol. What it provides is a detailed map of the biological pathways involved in weight management — the terrain your genetics has shaped. Genetics as a guide, not a guarantee. Test before you invest in any protocol.

Ready to see your GIPR rs1800437 genotype and all 34 weight management insights? Explore the Precision Peptide Genetic Test

The Precision Peptide Genetic Test analyzes how your genes influence weight management pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Frequently Asked Questions

Why was GIPR rs1800437 associated with tirzepatide but not GLP-1-only medications?

GIPR encodes one of two receptors activated by tirzepatide. When GIPR signaling is partially reduced — as with the rs1800437 C allele — the balance between GLP-1 and GIP receptor activation shifts. GLP-1-only medications don't engage GIPR at all, so this variant wouldn't create the same receptor-balance dynamic and wouldn't appear in GLP-1-only studies.

What is a GWAS and why does a 27,885-person study matter?

A GWAS — genome-wide association study — tests hundreds of thousands of genetic variants simultaneously across a large population to identify statistically significant associations with an outcome. At 27,885 participants, the 2026 Nature study had the statistical power to detect even modest genetic signals, and the rs1800437 finding passed a stringent genome-wide significance threshold.

What did the 2026 Nature study specifically find about rs1800437?

The study found rs1800437 significantly associated with gastrointestinal-related outcomes specifically in individuals using tirzepatide — a dual GLP-1/GIP receptor agonist — and not in those using GLP-1-only agonists. The C allele was the effect allele; the G allele showed a more favorable profile. Findings were directionally consistent across ancestries in meta-analysis.

What is the Glu354Gln substitution and why is it called a partial loss-of-function?

The Glu354Gln substitution replaces glutamic acid with glutamine at position 354 in the GIPR protein. This change alters the receptor's structure in a way research has characterized as reducing — but not eliminating — GIP receptor signaling capacity. Partial loss-of-function means the receptor still works, but with measurably reduced efficiency compared to the G allele form.

Can I be tested for GIPR rs1800437?

Yes. The PlexusDx Precision Peptide Genetic Test directly genotypes rs1800437 on the Illumina Global Screening Array — measured precisely from your DNA, not inferred from nearby variants. Your result is reported through the PlexusDx Results Portal as part of 34 weight management genetic insights, with a plain-language interpretation of your genotype.

Does knowing my GIPR genotype change how I should approach weight management?

Your GIPR genotype is one data point within 34 weight management insights in the PlexusDx panel. The test does not prescribe or recommend any approach. All 34 insights are designed to inform conversations with your healthcare provider about your biology — giving you and your provider a more complete genetic picture to work from, not a replacement for clinical judgment.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education